CVS sees upbeat 2024 revenue, plans to simplify drug pricing process
Reuters
Published Dec 05, 2023 06:59AM ET
Updated Dec 05, 2023 02:41PM ET
By Leroy Leo and Mariam Sunny
(Reuters) -CVS Health on Tuesday forecast 2024 revenue above market estimates and said it would simplify the structure through which its pharmacies get reimbursed for drugs, in a push for more transparency amid scrutiny on surging healthcare costs.
Under the new model, called CostVantage, the company's over 9,000 pharmacies will have a fixed markup and fees to define drug cost and related reimbursement with contracted insurers and pharmacy benefit managers (PBMs).
Currently, out-of-pocket drug prices are decided by a complex, multi-tiered network including insurers, drugmakers, pharmacies and PBMs, resulting in ambiguity around fees and markups to the original cost of the drug.
"We have to make a change because our consumers are demanding it, the government's demanding it, and we have the opportunity here to drive a much more transparent model," CEO Karen Lynch said at the company's investor day.
CostVantage will be introduced for commercial insurance plans from 2025 and is expected to benefit the pharmacy and consumer wellness unit, executives said.
The company's shares rose 4% in afternoon trade.
Lynch said CVS expects its long-term earnings growth to be at least 6%, with a recovery in margins from its Medicare Advantage plans in 2025 helping the year's adjusted earnings per share rise by as much as 9% to 10%.
It expects 2024 revenue of at least $366 billion, ahead of LSEG estimates of $345.81 billion.
Separately, shares of GoodRx, which offers discount coupons for prescription drugs, slumped nearly 10% as the new CVS program raised competitive concerns.
CVS also said its PBM unit, Caremark, will in 2025 launch a program called TrueCost to offer clients more visibility into prescription drug pricing and administrative fees.
PBMs, which work as middlemen between insurers and drugmakers, have faced increasing political pushback over their role in surging drug costs.
"This is a great first step, in that it's bringing transparency to one part of the drug supply chain," said Julie Balter from Alliance of Community Health (NYSE:CYH) Plans.
Get The News You Want
"But I do think we need to continue to push for transparency throughout; transparency in how the drugs are priced, in purchasing them, (and) in the rebate aggregators."
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.